PE20081443A1 - Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas - Google Patents
Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlasInfo
- Publication number
- PE20081443A1 PE20081443A1 PE2007001702A PE2007001702A PE20081443A1 PE 20081443 A1 PE20081443 A1 PE 20081443A1 PE 2007001702 A PE2007001702 A PE 2007001702A PE 2007001702 A PE2007001702 A PE 2007001702A PE 20081443 A1 PE20081443 A1 PE 20081443A1
- Authority
- PE
- Peru
- Prior art keywords
- valsartan
- microemulsion
- prepare
- methods
- dosage forms
- Prior art date
Links
- 239000004072 C09CA03 - Valsartan Substances 0.000 title abstract 3
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title abstract 3
- 229960004699 valsartan Drugs 0.000 title abstract 3
- 239000004530 micro-emulsion Substances 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 abstract 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- -1 FATTY ACID ESTER Chemical class 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 abstract 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 abstract 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 239000008346 aqueous phase Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 229940067606 lecithin Drugs 0.000 abstract 1
- 235000010445 lecithin Nutrition 0.000 abstract 1
- 239000000787 lecithin Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000012071 phase Substances 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Dispersion Chemistry (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) VALSARTAN, COMO PRINCIPIO ACTIVO Y b) UN VEHICULO QUE CONTIENE UN TENSOACTIVO, SELECCIONADO ENTRE ESTER DE ACIDO GRASO, LECITINA, COPOLIMEROS, ENTRE OTROS; UN COMPONENTE LIPOFILICO, TAL COMO MONOGLICERIDO, TRIGLICERIDO, ENTRE OTROS; Y UNO HIDROFILICO, TAL COMO PEG1450, PEG3350, PEG4000, ENTRE OTROS. DICHA COMPOSICION SE CARACTERIZA POR FORMAR UNA MICROEMULSION DE ACEITE EN AGUA CON EL MEDIO ACUOSO, GENERANDO UNA FASE INTERNA LIPOFILICA CONTENIENDO EL VALSARTAN COMO ACIDO LIBRE Y UNA FASE EXTERNA ACUOSA, CUYO TAMANO DE PARTICULA ES DE 300nm. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE HIPERTENSION, INSUFICIENCIA CARDIACA CONGESTIVA, NEFROPATIA DIABETICA, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86860406P | 2006-12-05 | 2006-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081443A1 true PE20081443A1 (es) | 2008-12-23 |
Family
ID=39365945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001702A PE20081443A1 (es) | 2006-12-05 | 2007-12-03 | Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100035949A1 (es) |
| EP (1) | EP2111217A2 (es) |
| JP (1) | JP2010511722A (es) |
| KR (1) | KR20090086281A (es) |
| CN (1) | CN101541306A (es) |
| AR (1) | AR064104A1 (es) |
| AU (1) | AU2007333355B2 (es) |
| BR (1) | BRPI0720077A2 (es) |
| CA (1) | CA2671495A1 (es) |
| CL (1) | CL2007003484A1 (es) |
| MX (1) | MX2009005947A (es) |
| PE (1) | PE20081443A1 (es) |
| RU (1) | RU2009125613A (es) |
| TW (1) | TW200840596A (es) |
| WO (1) | WO2008073731A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102740841A (zh) * | 2009-12-08 | 2012-10-17 | 株式会社一和 | 含有20-O-β-D-吡喃葡糖基-20(S)-原人参二醇的固体分散体 |
| WO2014009434A1 (en) | 2012-07-11 | 2014-01-16 | Sandoz Ag | Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate |
| JP6882321B2 (ja) | 2015-12-09 | 2021-06-02 | フォスファージニクス リミテッド | 医薬製剤 |
| KR20190032265A (ko) * | 2015-12-09 | 2019-03-27 | 포스파제닉스 리미티드 | 약제학적 제형 |
| IL267006B2 (en) | 2016-12-21 | 2024-11-01 | Phosphagenics Ltd | Process for phosphorylation of a complex alcohol with p4o10 at high temperatures, and products thereof |
| KR101920628B1 (ko) * | 2017-04-12 | 2018-11-22 | 대원제약주식회사 | 안지오텐신 수용체 길항제를 포함하는 약제학적 조성물 |
| CN111183991A (zh) * | 2020-03-03 | 2020-05-22 | 安徽金敦福农业科技有限公司 | 一种含有百里香酚的农药组合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US20020102301A1 (en) * | 2000-01-13 | 2002-08-01 | Joseph Schwarz | Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof |
| US20020132839A1 (en) * | 2000-06-22 | 2002-09-19 | Ganter Sabina Maria | Tablet formulations comprising valsartan |
| WO2006050123A1 (en) * | 2004-10-29 | 2006-05-11 | Novartis Ag | Spontaneously dispersible pharmaceutical compositions |
| MX2007012947A (es) * | 2005-04-18 | 2008-04-09 | Rubicon Res Pvt Ltd | Composiciones biomejoradas. |
-
2007
- 2007-12-03 AR ARP070105388A patent/AR064104A1/es unknown
- 2007-12-03 JP JP2009540402A patent/JP2010511722A/ja not_active Withdrawn
- 2007-12-03 RU RU2009125613/15A patent/RU2009125613A/ru not_active Application Discontinuation
- 2007-12-03 KR KR1020097013926A patent/KR20090086281A/ko not_active Withdrawn
- 2007-12-03 US US12/517,105 patent/US20100035949A1/en not_active Abandoned
- 2007-12-03 AU AU2007333355A patent/AU2007333355B2/en not_active Expired - Fee Related
- 2007-12-03 WO PCT/US2007/086226 patent/WO2008073731A2/en not_active Ceased
- 2007-12-03 BR BRPI0720077-3A2A patent/BRPI0720077A2/pt not_active IP Right Cessation
- 2007-12-03 CA CA002671495A patent/CA2671495A1/en not_active Abandoned
- 2007-12-03 EP EP07871651A patent/EP2111217A2/en not_active Withdrawn
- 2007-12-03 CN CNA2007800441500A patent/CN101541306A/zh active Pending
- 2007-12-03 MX MX2009005947A patent/MX2009005947A/es not_active Application Discontinuation
- 2007-12-03 PE PE2007001702A patent/PE20081443A1/es not_active Application Discontinuation
- 2007-12-04 CL CL200703484A patent/CL2007003484A1/es unknown
- 2007-12-04 TW TW096146195A patent/TW200840596A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007333355A1 (en) | 2008-06-19 |
| CA2671495A1 (en) | 2008-06-19 |
| JP2010511722A (ja) | 2010-04-15 |
| WO2008073731A2 (en) | 2008-06-19 |
| BRPI0720077A2 (pt) | 2013-12-24 |
| TW200840596A (en) | 2008-10-16 |
| CL2007003484A1 (es) | 2008-07-11 |
| WO2008073731A3 (en) | 2009-03-19 |
| CN101541306A (zh) | 2009-09-23 |
| MX2009005947A (es) | 2009-06-17 |
| AU2007333355B2 (en) | 2011-10-20 |
| AR064104A1 (es) | 2009-03-11 |
| US20100035949A1 (en) | 2010-02-11 |
| RU2009125613A (ru) | 2011-01-20 |
| EP2111217A2 (en) | 2009-10-28 |
| KR20090086281A (ko) | 2009-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081443A1 (es) | Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas | |
| ES2529728T3 (es) | Combinaciones de principios activos nematicidas que comprenden fluopiram y fluensulfone | |
| AR092403A1 (es) | Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso | |
| AR081542A1 (es) | Composiciones de emulsiones farmaceuticas con bajo contenido de aceite que comprenden un progestageno | |
| MX2015011462A (es) | Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones. | |
| PE20110449A1 (es) | Emulsiones modificadas de liberacion de medicina para aplicacion a la piel o la mucosa vaginal | |
| CO6290641A2 (es) | Preparacion de capsula que contiene los ingredientes farmaceuticamente activos liquidos y solidos, la cual presenta exelentes propiedades de los ingredientes farmaceuticamente activos | |
| AR071123A1 (es) | Composiciones para duchas y banos de inmersion | |
| PE20091965A1 (es) | Encapsulacion de agentes biologicamente activos | |
| PE20110943A1 (es) | Formulacion oral solida de alisquireno | |
| UY32760A (es) | Composición farmacéutica para un inhibidor de proteasa del virus de la hepatitis c | |
| AR059829A1 (es) | Sistemas estables de nanocapsulas para la administracion de moleculas activas | |
| AR092402A1 (es) | Nanoparticula polimerica de finasterida, suspension acuosa conteniendo a la misma, composicion para tratamiento de alopecia, proceso de preparacion de dicha composicion, y su uso | |
| EA201490802A1 (ru) | Препараты этанерцепта, стабилизированные меглюмином | |
| NZ596657A (en) | Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof | |
| CL2011002053A1 (es) | Composicion farmaceutica de espuma en aerosol en emulsion de aceite en agua que comprende un agente farmaceuticamente activo, agua, aceite, disolvente organico, componente tensoactivo, y propulsor; procedimiento de preparacion; uso para tratar enfermedades, o afecciones de la piel. | |
| CO6280437A2 (es) | Una composicion de emulsion de aceite en agua que tiene una fase de agua y nua fase de aceite comprendiendo un modificador polimerico y un compuesto activo agricolamente | |
| PE20110302A1 (es) | Formulacion farmaceutica de un anticuerpo contra p-selectina | |
| PE20090064A1 (es) | Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende | |
| MX2009009997A (es) | Preparacion de la capsula de tamibarotene. | |
| PE20131108A1 (es) | Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina | |
| MX2021009921A (es) | Preformulacion de lipidos de liberacion sostenida y composicion farmacetica de liberacion sostenida inyectable en la forma de una solucion de lipidos que contiene a la misma. | |
| CO6321129A2 (es) | Inhibidor de la cristalizacion y su uso en capsulas de gelatina | |
| PE20020833A1 (es) | Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponisibilidad oral | |
| CL2008003002A1 (es) | Composición farmacéutica inyectable intravenosa en forma de emulsión aceite en agua que comprende al toxoide larotaxel (xrp9881) o cabazitaxel (xrp6258) disuelto en lecitina, y al tensioactivo aniónico fosfatidilglicerol o acido fosfatidico; proeceidimiento para su preparacion, útil como antineoplástico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |